Literature DB >> 11448452

Agonist-induced functional desensitization of recombinant human 5-HT2 receptors expressed in CHO-K1 cells.

R H Porter1, C S Malcolm, N H Allen, H Lamb, D F Revell, M J Sheardown.   

Abstract

The desensitization characteristics of recombinant human 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptors (VSV and INI isoforms) stably expressed in CHO-K1 (Chinese hamster ovary) cells was investigated by calcium fluorimetry. Comparative desensitization characteristics of the agonists 5-HT, m-chlorophenylpiperazine (mCPP), and 2,5-dimethoxy-4-iodoamphetamine hydrobromide (DOI) were performed. Human 5-HT(2C (INI)) receptors exhibited a greater degree of desensitization to all agonists tested than edited 5-HT(2C (VSV)) receptors. A 2-hr exposure to 5-HT resulted in a significantly larger reduction in response upon re-exposure to 5-HT at 5-HT(2C (INI)) receptors, as compared to 5-HT(2C (VSV)) receptors (72% and 47% respectively, P < 0.01). Both receptor isoforms were expressed at similar densities. Human 5-HT(2B) receptors exhibited the most dramatic degree of desensitization, with prior exposure to 5-HT reducing subsequent response to 5-HT by 80%, with an extremely rapid time-course (t(1/2) < 5 min). The response at 5-HT(2A) receptors was reduced by 54%. The partial agonists mCPP and DOI also elicited desensitization, generally in line with their relative efficacies at each receptor, but exhibited more rapid kinetic profiles than 5-HT. Heterologous desensitization of an endogenously expressed G(q/11)-coupled purinergic receptor was also examined following preincubation of the cell lines with 10 microM 5-HT. Only stimulation of 5-HT(2C (VSV)) receptors resulted in a profound attenuation of subsequent ATP mediated responses. These results demonstrate differing degrees of both homologous and heterologous desensitization of 5-HT(2) receptors. Additionally, the different desensitization profiles of 5-HT(2C (INI)) and 5-HT(2C (VSV)) receptor may be due to signal transduction differences caused by RNA editing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448452     DOI: 10.1016/s0006-2952(01)00677-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Serotonergic transmission at Merkel discs: modulation by exogenously applied chemical messengers and involvement of Ih currents.

Authors:  Weipang Chang; Hirosato Kanda; Ryo Ikeda; Jennifer Ling; Jianguo G Gu
Journal:  J Neurochem       Date:  2017-03-27       Impact factor: 5.372

2.  Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats.

Authors:  Aska Hayashi; Masanori Suzuki; Masao Sasamata; Keiji Miyata
Journal:  Psychopharmacology (Berl)       Date:  2004-10-21       Impact factor: 4.530

Review 3.  Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.

Authors:  P De Deurwaerdère; M Lagière; M Bosc; S Navailles
Journal:  Exp Brain Res       Date:  2013-04-25       Impact factor: 1.972

4.  Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.

Authors:  B Schaerlinger; P Hickel; N Etienne; L Guesnier; L Maroteaux
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

5.  Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice.

Authors:  Pablo R Moya; Meredith A Fox; Catherine L Jensen; Justin L Laporte; Helen T French; Jens R Wendland; Dennis L Murphy
Journal:  BMC Pharmacol       Date:  2011-04-07

6.  Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice.

Authors:  Tobias Buchborn; Taylor Lyons; Thomas Knöpfel
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

7.  Serotonin: an overlooked regulator of endocytosis and endosomal sorting?

Authors:  Gregory Redpath; Nikita Deo
Journal:  Biol Open       Date:  2022-01-25       Impact factor: 2.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.